Background. Studies assessing outcomes in occult breast cancer have often included women treated before the routine use of magnetic resonance imaging (MRI). This study examined outcomes for patients presenting with axillary adenopathy and no primary breast tumor detectable by MRI or other imaging methods. Methods. All patients with axillary nodal metastases consistent with breast carcinoma and no breast primary tumor detectable by physical exam, mammography, or MRI treated between 1 January 1996 and 30 June 2011 were identified from an institutional database. Data were collected on local, regional, and distant recurrences. Results. For the study, 38 patients were identified. Modified radical mastectomy (MRM) was performed for 13 of the patients, whereas 25 of the patients underwent axillary dissection (ALND) and whole-breast radiotherapy (WBRT). Most of the women had pathologic N1 disease [median number of positive nodes, 2 (MRM cohort) and 3 (ALND ? WBRT cohort); p = 0.38]. All the patients received chemotherapy, and 30 (79%) of the 38 patients received an anthracycline and taxane. Regional nodal radiation was used for 60% of those with ALND ? WBRT and for all 46% of the MRM patients who received chest wall radiotherapy. During a median follow-up period of 7 years, there were no nodal recurrences. Two patients treated with ALND ? WBRT had in-breast recurrences, whereas none in the MRM group experienced a local recurrence. The proportion that experienced distant disease was similar between the MRM cohort (1 of 13) and the ALND ? WBRT cohort (2 of 25). Conclusion. Breast cancer presenting as axillary adenopathy with no detectable primary tumor is rare. Breast conservation with WBRT is a viable option for patients with a diagnosis of occult breast cancer and a negative preoperative MRI.
Occult breast cancer denotes the clinical scenario of axillary nodal metastases consistent with a breast carcinoma arising in the absence of any identifiable primary breast tumor (pT0N?) despite full clinical and radiologic assessment. This presentation is uncommon, with contemporary reports suggesting that less than 0.3% of breast cancer cases are occult. 1, 2 Historically, the surgical management of these patients mandated a modified radical mastectomy (MRM). 3 Preoperative magnetic resonance imaging (MRI) has become the standard of care for breast cancer patients with axillary metastases whose clinical examination, mammography, and ultrasound have failed to identify the primary tumor. 4 The use of MRI identifies a suspect lesion in 72% of cases with normal mammography and ultrasound, and the majority of these ([85%) prove to be the primary breast carcinoma on biopsy. 5 As a result of the enhanced MRI sensitivity, any putative primary lesion requires pathologic confirmation through either a secondlook ultrasound and biopsy or MRI-guided biopsy, or, failing these, excisional biopsy before clinicians decide on management.
Given the low incidence of occult breast cancer, evidence assessing outcomes after treatment often has been accumulated during long study periods, with inherent heterogeneity in both the diagnosis and treatment. Axillary lymph node dissection (ALND) followed by whole-breast radiotherapy (WBRT) has emerged as a viable treatment option. [6] [7] [8] A recent meta-analysis identified studies comprising only 241 patients, less than half of whom had a preoperative breast MRI, 9 and concluded that equivocal rates of local control and overall survival are achievable with breast ALND and WBRT. 10 Notwithstanding this conclusion, population studies suggest that almost half of patients with occult breast cancer still are treated with MRM. 11, 12 Currently, the diagnosis of occult breast cancer should be limited to patients who present with an axillary metastasis but no clinical, mammographic, sonographic, or MRI evidence of breast disease. Accordingly, this study aimed to compare disease-free survival (DFS) between patients with true occult breast cancer who underwent MRM and those treated with ALND and WBRT.
MATERIALS AND METHODS
Patients treated for an occult breast cancer (pT0N?) between 1 January 1996 and 30 June 2011 were identified from a prospective institutional database after receipt of Memorial Sloan Kettering Cancer Center (MSKCC) institutional review board approval. Occult breast cancer was defined as adenocarcinoma histologically consistent with a breast origin that presented with axillary metastases in the absence of primary breast tumor on physical examination, imaging, or preoperative biopsy. 9 Patients were eligible for inclusion in the study if they presented with biopsy-proven axillary lymph node metastases and had been evaluated with a breast MRI before definitive axillary surgery.
All MRI studies before July 2009 were performed on a 1.5-T MRI scanner. After that date, both 1.5-T and 3-T MRI scanners were used within the department. All patients underwent ALND and either mastectomy or primary breast radiotherapy. Throughout the entire study period, MRM or ALND with WBRT were offered as treatment options in the scenario of occult breast cancer.
Patients who had not been evaluated with a breast MRI before ALND and patients with a history of prior ipsilateral breast cancer were excluded from the study. Those with a history of contralateral breast cancer were excluded because axillary metastases in most of these cases represented probable contralateral axillary metastases. Patients for whom the biopsy histology definitively showed that the axillary metastasis was of non-breast origin also were excluded. Patients in whom the presenting mass was thought to be arising in the axillary tail of the breast and not a true nodal metastasis also were excluded.
Patient characteristics at presentation, including clinical stage and systemic staging investigations performed, were recorded. The method of initial axillary node biopsy type (excisional vs needle biopsy) and results including the use of additional immunohistochemical markers of CK7 and CK20 in addition to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) were evaluated. Breast MRI results, including the use of diagnostic excisional biopsy, were noted. Treatment details incorporating surgery and the use of chemotherapy, adjuvant radiotherapy, and endocrine therapy were available. Patient outcomes, including the date of the last follow-up visit, the occurrence of ipsilateral or contralateral breast events, regional or distant metastases, and overall survival were collected.
Categorical variables were summarized with number and percentage, whereas continuous variables were summarized using median and range. To test for differences between groups, Fisher's exact test was used for categorical variables and the Kruskal-Wallis test for continuous variables. The STEEP (standardized definitions for efficacy end points in adjuvant breast cancer trials) system was proposed in 2007 to standardize the definitions used as breast cancer clinical trial end points. 13 For assessment of DFS in this study, we used the end points of invasive DFS and ductal carcinoma in situ (DCIS) as outlined in the STEEP system. Accordingly, the occurrence of ipsilateral breast tumor recurrence or contralateral breast cancer (in situ and invasive), regional or distant recurrence, or death attributable to any cause was considered a primary end point. The time was calculated from the date of ALND to the date of recurrence or death. Patients alive without recurrence were censored on the date of their last visit. The Kaplan-Meier method estimated the time to recurrence. A p value lower than 0.05 was considered statistically significant. All statistical analyses were conducted with R software version 3.2.5 (R Core Development Team, Vienna, Austria).
RESULTS
During the study period, 38 patients who met the eligibility criteria were identified. During the same period, 18,994 patients underwent surgical treatment for invasive breast cancer at our center. Of the 38 patients, 25 (66%) were treated with ALND and WBRT, whereas the remaining 13 (34%) underwent an MRM ( Table 1) .
The patients with mobile adenopathy, clinical stage N1, comprised 88% of those in the ALND ? WBRT group and 77% of those in the MRM group. Almost half of the patients had their diagnosis determined by an excisional biopsy of the palpable lymph node (n = 18, 47%). In more recent years, needle biopsy (either core-needle biopsy or fine-needle aspiration) was more frequently used, with the diagnosis for 77% of patients presenting between 2009 and samples were subject to immunohistochemical staining for CK7 and CK20, but for those that had the staining, CK7 was positive in the majority of cases, and CK20 was not positive in any case.
Systemic staging was performed for most of the patients, with positron emission tomography-computed tomography (PET-CT) (n = 24, 63%) or CT and bone scan (n = 12, 32%) comprising the most common staging methods. Some patients had staging after excisional biopsy. For the 10 patients staged with a PET-CT before axillary surgery, the median axillary standard uptake value maximum was 13.7 (range 3.6-24).
All the patients were evaluated with an MRI preoperatively. Five of the patients underwent an MRI-guided biopsy before definitive surgery, and the results were benign. An additional 11 patients (44%) who chose breast conservation underwent a breast imaging-guided excision of a radiologic abnormality in the ipsilateral breast, with none yielding DCIS or invasive breast cancer (Table 2 ). For two patients treated with mastectomy, the final pathology identified a focus of DCIS with microinvasion, and one of the two had a preoperative MRI-guided biopsy that returned a benign diagnosis. A retrospective review of the MRI was not performed for these two patients, or for any of the other patients in this study.
Among the 29 patients who underwent surgery as the first treatment, the median number of positive axillary nodes was two for the entire group and three for the 17 patients whose diagnosis was determined by needle biopsy (range . The final burden of axillary disease was similar between those who underwent ALND with WBRT and those who had MRM, with 60 and 54%, respectively, having three or fewer positive nodes. In 22 of 38 cases (58%), the nodal metastases were ER-negative, with the triple-negative subtype most commonly represented.
Neoadjuvant chemotherapy (NAC) was given to nine patients (Table 3) . Selection of the patients for NAC was at the discretion of the treating surgeon and not determined by a departmental guideline. Residual disease in axillary nodes was identified in three patients. Among the six patients whose cancer was diagnosed by excisional node biopsy, one had residual disease. Two of the three whose diagnosis was determined by core needle biopsy also had residual disease. No in situ or invasive disease was identified in the breast of the four patients in the MRM group treated with NAC. All the patients who elected breast conservation received adjuvant WBRT. The regional nodes were included in the field of radiation in 60% of these cases. In the MRM group, 46% of the patients were treated with postmastectomy radiotherapy, and in all of these cases, the treatment encompassed regional nodal radiation. Supraclavicular nodes were treated in all 21 cases that received regional nodal irradiation, with treatment additionally to the axilla for nine patients and to both the axilla and internal mammary nodes for three patients ( Table 3) .
The median follow-up period among the survivors was 7 years (range, 1.5-18 years). No local or regional recurrence events were noted in the MRM group. In the WBRT group, 2 (8%) of the 25 patients experienced an ipsilateral breast cancer (Table 4) . One patient had ER-positive disease, and the ipsilateral breast cancer was diagnosed 4.2 years after her initial surgery while she still was receiving adjuvant tamoxifen. The other ipsilateral breast tumor was in a patient with initial ER-negative disease 4.6 years after surgery. Overall, DFS did not appear to differ significantly between the two groups, as illustrated by the Kaplan-Meier curve in Fig. 1 . The sample was too small for formal statistical comparison of DFS between the two groups, but as illustrated by the Kaplan-Meier curve (Fig. 1) , the confidence intervals for DFS at 10 years were wide and overlapping, suggesting no significant difference in DFS between the two groups at 10 years.
DISCUSSION
Occult breast cancer is a clinical entity not commonly encountered, as evidenced by the dearth of studies identified in the aforementioned recent meta-analysis. 9 In the current study, occult breast cancer represented less than ALND axillary lymph node dissection; WBRT whole-breast radiation therapy; MRM modified radical mastectomy; ER estrogen receptor; HER2 human epidermal growth factor receptor 2
One patient whose diagnosis was determined by core needle biopsy had complete pathologic response after neoadjuvant chemotherapy, with no positive nodes identified on pathologic analysis of ALND ALND axillary lymph node dissection; WBRT whole-breast radiation therapy; MRM modified radical mastectomy 0.5% of the breast cancers surgically treated at our center during the study period. The application of breast MRI as a routine component in the evaluation of patients whose mammography and ultrasound are unable to locate a breast primary will undoubtedly further diminish the frequency with which women who have truly imaged occult breast cancers are identified. Historically, the rate of identifying a focus of invasive breast cancer upon histologic analysis of mastectomy specimens in patients with clinical-and imaging-occult breast cancer has ranged from 35 3,14 to 82%. 15 The variation is explainable because the studies examined practice during long periods, with inconsistency in the threshold for pre-mastectomy biopsy of indeterminate areas on mammography.
The experience with MRI in the setting of occult breast cancer has been gleaned during a shorter period, and it is accepted that for 70-80% of cases with normal physical examination and mammography, MRI will identify a lesion suspected of a primary breast cancer. 5 The false-negative rate for MRI in this setting is not as well reported, with few contemporary studies reporting on patients with a negative MRI who undergo a mastectomy. Orel et al. 16 identified two false-negative MRIs among 22 patients (9%) between 1993 and 1997. In the current study, 2 (15%) of the 13 patients treated with mastectomy in which MRI had not identified a primary tumor showed an area of DCIS with microinvasion on the final pathology.
Because MRI identifies the primary tumor in a majority of patients presenting with mammographically occult breast cancer, the small proportion of women in whom no primary tumor is detectable by any method, including MRI, must have a low tumor burden. In conventional breastconserving therapy, it is assumed that subclinical disease remains even after lumpectomy with clear margins. 17 Radiation is used to eradicate this undetectable disease. Several randomized trials of lumpectomy with WBRT versus MRM have shown equivalent outcomes. 18, 19 With the adoption of breast MRI, which is more sensitive than conventional imaging, the same rationale has been used to conserve the breast for women presenting with nodal metastases and no identifiable primary. None of the comparative studies have shown a significant increase in rates of locoregional recurrence for patients treated with WBRT versus MRM. 7, 14, 20, 21 Meta-analysis shows similar rates of locoregional control, distant metastasis, and mortality between patients who undergo MRM and those who have ALND with WBRT. 10 The addition of WBRT when the breast is preserved is an important component of the treatment because its omission results in a significantly higher rate of locoregional recurrence caused by failure to either excise or irradiate the breast primary and perhaps a worse long-term survival. 14, 22, 23 To date, studies on occult breast cancer have not limited their cohort to patients with true occult primaries by current standards as defined by a negative breast MRI. Our study is the largest series to date comparing outcomes for patients with truly occult breast cancer (not detectable by any clinical or radiologic investigation including MRI) treated with either mastectomy or WBRT. Our findings echo those of previous reports showing that breast conservation for patients with true occult breast cancer is a safe option, with low rates of local and regional recurrence. In our series, 2 (8%) of 25 patients in whom the breast was preserved and treated with WBRT experienced an in-breast recurrence without distant metastases. Previous reports of in-breast recurrences for contemporarily treated cohorts range from 0 (of 24 patients) 10 to 6% (average of 5 years after diagnosis). Buoyed by the success of neoadjuvant chemotherapy in obtaining high rates of axillary complete response in women who present with node-positive breast cancer, there is interest in axillary conservation, particularly for patients with triple-negative and HER2-positive breast cancer. 24, 25 In the recent report by Rueth et al. 10 describing patients with occult breast cancer, a complete axillary response was seen in 60% of the patients who had an ALND after neoadjuvant chemotherapy. The high rate of both ERnegative cancer (58%) and triple-negative breast cancer (33%) in this cohort would seem to support the neoadjuvant chemotherapy approach for many of these patients. Our subtype findings are similar to those in previously published occult breast cancer cohorts, with rates of ER negativity ranging from 32 to 63% and triple-negative disease reported in 18-33% of cases. 10, 20, 22, 26 Conceivably, for carefully selected patients who present with occult primary breast cancer and demonstrate an excellent clinical and radiologic axillary response to neoadjuvant systemic therapy, a sentinel lymph node biopsy (SLNB) for axillary staging may have a role. Three prospective studies have shown the accuracy of SLNB for women with axillary nodal metastases who receive neoadjuvant chemotherapy, become clinically node-negative, and undergo dual-agent mapping with at least three nodes retrieved. [27] [28] [29] Techniques to ensure removal of nodes with biopsy-confirmed metastasis, including pathologic assessment for tumor regression 30 and the placement of a biopsy marker clip, 31 may improve the accuracy of nodal staging if certain patients with occult breast cancer are selected for SLNB after neoadjuvant chemotherapy.
As a retrospective study of only 38 patients, the limitations of this study must be acknowledged. Although the cohort was selected to ensure standardization of preoperative evaluation with MRI, the patients were accrued during a 15-year study period. This period coincided with many important treatment advances in breast cancer management. This is exemplified by the expanding role of neoadjuvant chemotherapy, the use of which was not a standard guideline for our patients during the study period. For a high proportion of the patients, the diagnosis was determined by an excisional lymph node biopsy, which still may be required occasionally in the setting of a suspected lymphoma, but needle biopsy should be used as the current standard of care for patients presenting with clinical lymphadenopathy. 32 Most importantly, the small numbers in the study precluded the ability to identify patients with occult breast cancer who were at highest risk for local or regional recurrence and to determine whether a group exists for whom primary breast radiotherapy may not represent sufficient local control.
With the universal recognition of the role for breast MRI in evaluation of patients who present with axillary lymph node metastases and normal physical examination, mammography, and ultrasound, the true definition of occult breast cancer must now include a negative MRI. In our cohort, whose members all received contemporary chemotherapy, the outcomes for those with breast conservation through WBRT after ALND were comparable with those for the patients who underwent modified radical mastectomy with low rates of local recurrence, verifying breast conservation as a real option for those with true occult breast cancer. Recent studies suggest that further progress may be achieved for women with occult breast cancer who undergo neoadjuvant chemotherapy and thereby avoid an ALND.
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